⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
URGN News
UroGen Pharma Ltd. Ordinary Shares
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
globenewswire.com
URGN
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
globenewswire.com
URGN
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
globenewswire.com
URGN
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
globenewswire.com
URGN
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
globenewswire.com
URGN
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
globenewswire.com
URGN